Reshma Kewalramani
Saturday, July 27, 2019
Vertex Pharmaceuticals (NASDAQ: VRTX) $43.4b Ms. Reshma Kewalramani promoted to CEO-elect will join Board succeed Jeffrey Leiden continue as ExCOB Q1 2020 Kewalramani:
Base Salary: $800,000 w/ increase upon promotion to $1,150,000; Target annual bonus of 120% of base salary; Continued participation in equity programs upon promotion 2021 aggregate target grant date fair value of $11,000,000